We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A clinical trial of Eli Lilly’s antibody candidate treatment for COVID-19 was paused Tuesday following a safety incident — awkward timing as the company has just applied to the FDA for an Emergency Use Authorization (EUA) for the product.
